Steen Meier Knudsen
Founder & Chief Scientific OfficerDr. Steen Meier Knudsen, Ph.D, Co-Founded Allarity Allarity Therapeutics, Inc. in 2004 and has been its Chief Scientific Officer since July 2021 and was its Board of Directors from 2016 to 2020. He served as a Director of Allarity Therapeutics A/S since 2004 until October 7, 2020. He serves as Director of the wholly-owned subsidiary Oncology Venture ApS since 2015. He served as Chief Executive Officer at Allarity Therapeutics A/S from 2004 to 2006. Dr. Knudsen is Founder of Oncology Venture ApS and Co-Founder of MPI. Dr. Knudsen serves as the Chief Executive Officer of MPI, Inc. He is Professor Emeritus of Systems Biology and was its Professor and has extensive expertise in mathematics, bioinformatics, biotechnology and systems biology. In addition, Dr. Knudsen is the inventor of Drug Response Prediction, which Oncology Venture has a license from MPI to use. He represents the majority shareholder MPI. Dr. Knudsen’s current Involvement with and commitments to other companies, Medical Prognosis Institute A/S, Chief Scientific Officer and Member of the Board, Medical Prognosis Institute Inc., Chief Executive Officer and Member of the Board, Oncology Venture ApS, Dr. Knudsen holds M.Sc degree in Engineering from the Technical University of Denmark, Ph.D. in Microbiology from the University of Copenhagen, Postdoc work in Computational Biology and Bioinformatics (CBB) at Harvard University.
Positions
- Company NameAllarity Therapeutics, Inc.Stock CodeALLRPositionFounder & Chief Scientific OfficerColleagues
- THThomas H. JensenFounder, CEO & Director
- GWGerald W. McLaughlinIndependent Chairman of the Board
- JRJeremy R. GraffPresident & Chief Development Officer
- JSJeffrey S. ErvinChief Financial Officer
- JLJose L. IglesiasConsultant Chief Medical Officer
- DDDaniel Douglas Von HoffMember of Scientific Advisory Board
- UAUrsula A. MatulonisMember of Scientific Advisory Board
- JAJoyce Ann O'ShaughnessyMember of Scientific Advisory Board
